High flow nasal cannula in COVID-19: a literature review

Aslıhan GÜRÜN KAYA, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Miraç ÖZ, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Serhat EROL, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Fatma ÇİFTÇİ, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Aydın ÇİLEDAĞ, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Akın KAYA (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Tüberküloz ve Toraks
0 0
Yıl: 2020 Cilt: 68 Sayı: 2 Sayfa Aralığı: 168 - 174 Metin Dili: İngilizce DOI: 10.5578/tt.69807 İndeks Tarihi: 22-11-2020

High flow nasal cannula in COVID-19: a literature review

Öz:
In recent years, high flow nasal cannula (HFNC) is a respiratory support system that has become prominent in the treatment of respiratory failure. HFNCprovides higher concentration and flow of oxygen, resulting in decreasinganatomic dead space by preventing rebreathing and ensure positive end-expiratory. However, in COVID-19, the usage of HFNC is much controversial dueto concerns about the benefits and risk of aerosol-dispersion. Considering thedebates about the use of HFNC, we reviewed the literature related to theusage of HFNC in COVID-19. The available reports suggest that HFNC provides high concentrations of oxygen to the patients, who can not reach withconventional devices. HFNC can reduce the requiring of intubation in patientswith COVID-19, and it can decrease the length of intensive care unit stay, andcomplications related to mechanical ventilation. Also HFNC can in achievingapneic oxygenation in patients during airway management. Besides that, theuse of high-flow oxygen cannulas can produce aerosols. So, HFNC treatmentshould be carried out in a negative pressure room; when it is not possible,devices should be undertaken in a single room.
Anahtar Kelime:

COVID-19’da yüksek akımlı nazal kanül oksijen kullanımı: literatür taraması

Öz:
Yüksek akımlı nazal kanül oksijen (YANKO) tedavisi, solunum yetmezliği tedavisinde son yıllarda öne çıkan solunum destek sistemidir. YANKO tedavisi ile, yüksek akım ve konsantrasyonlarda oksijen uygulanarak anatomik ölü boşlukta azalmanın yanı sıra, sürekli bir ekspiratuar pozitif havayolu basıncı sağlanır. YANKO tedavisinin olumlu etkilerinin yanı sıra, aerosol oluşumunu artırma riski nedeni ile COVID-19 pandemisinde kullanımına dair tartışmalar mevcuttur. COVID-19 pandemisinde, YANKO kullanımı ile ilgili çekinceler dikkate alınarak, derlememizde COVID-19 pandemisinde YANKO kullanımı ile ilgili literatür bilgisi gözden geçirilmiştir. Literatür taramamız sonucunda ulaşılan çalışmalar ve raporlarda, YANKO’nin geleneksel cihazlarla ulaşamayan hastalara yüksek konsantrasyonlarda oksijen sağladığını göstermektedir. YANKO, COVID-19 hastalarında entübasyon ihtiyacını azaltabilir ve yoğun bakım ünitesinde kalış süresini ve mekanik ventilasyonla ilgili komplikasyonları azaltabilir. Ayrıca YANKO, entübasyon sırasında preoksijenizasyonda kullanılabilir. Bununla birlikte YANKO kullanımı aerosol oluşumuna neden olabilmektedir. Bu nedenle, YANKO tedavisi negatif basınçlı bir odada, bu durum mümkün olmadığında ise hastanın bir odada izole edilerek uygulanması önerilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Coronavirus disease (COVID-19) Situation Report – 152 Available at: https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200620-covid-19-sitrep-152.pdf Access: 20 June 2020 [
  • 2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 202010.1001/ jama.2020.1585.
  • 3. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infectious Diseases 2020;20(6):656-7.
  • 4. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-4.
  • 5. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID- 19). StatPearls. Treasure Island (FL)2020.
  • 6. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J 2020;55(5).
  • 7. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372(23):2185-96.
  • 8. Rochwerg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med 2019;45(5):563- 72.
  • 9. Spicuzza L, Schisano M. High-flow nasal cannula oxygen therapy as an emerging option for respiratory failure: the present and the future. Ther Adv Chronic Dis 2020;11:2040622320920106.
  • 10. 1Nagata K, Morimoto T, Fujimoto D, et al. Efficacy of highflow nasal cannula therapy in acute hypoxemic respiratory failure: decreased use of mechanical ventilation. Respir Care 2015;60(10):1390-6.
  • 11. Thille AW, Muller G, Gacouin A, et al. Effect of postextubation high-flow nasal oxygen with noninvasive ventilation vs high-flow nasal oxygen alone on reintubation among patients at high risk of extubation failure: a randomized clinical trial. JAMA 2019;322(15):1465-75.
  • 12. Ling Y, Qu R, Luo Y. Clinical analysis of the first patient with imported Middle East respiratory syndrome in China. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015;27(8):630-4.
  • 13. Luo Y, Ou R, Ling Y, Qin T. The therapeutic effect of high flow nasal cannula oxygen therapy for the first imported case of Middle East respiratory syndrome to China. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015;27(10):841-4.
  • 14. Rello J, Perez M, Roca O, et al. High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v. J Crit Care 2012;27(5):434-9.
  • 15. Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One 2010;5(5).
  • 16. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth 202010.1007/s12630-020-01740-2.
  • 17. Ottestad W, Sovik S. COVID-19 patients with respiratory failure: what can we learn from aviation medicine? Br J Anaesth 202010.1016/j.bja.2020.04.012.
  • 18. He G, Han Y, Fang Q, et al. Clinical experience of highflow nasal cannula oxygen therapy in severe COVID-19 patients. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49(2):232-9.
  • 19. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62.
  • 20. Lagi F, Piccica M, Graziani L, et al. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. Euro Surveill 2020;25(17).
  • 21. Geng S, Mei Q, Zhu C, et al. High flow nasal cannula is a good treatment option for COVID-19. Heart & Lung. 202010.1016/j.hrtlng.2020.03.018.
  • 22. Barrasa H, Rello J, Tejada S, et al. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med 202010.1016/j. accpm.2020.04.001.
  • 23. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475-81.
  • 24. Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID- 19) in Taizhou, Zhejiang, China. Infection 202010.1007/ s15010-020-01432-5.
  • 25. Boccatonda A, Groff P. High-flow nasal cannula oxygenation utilization in respiratory failure. Eur J Intern Med 2019;64:10-4.
  • 26. Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care 2020;10(1):37.
  • 27. Karamouzos V, Fligou F, Gogos C, Velissaris D. High flow nasal cannula oxygen therapy in adults with COVID-19 respiratory failure. A case report. Monaldi Arch Chest Dis 2020;90(2).
  • 28. Rali AS, Nunna KR, Howard C, Herlihy JP, Guntupalli KK. High-flow Nasal Cannula Oxygenation Revisited in COVID-19. Card Fail Rev 2020;6:e08.
  • 29. Bocchile RLR, Cazati DC, Timenetsky KT, Serpa Neto A. The effects of high-flow nasal cannula on intubation and re-intubation in critically ill patients: a systematic review, meta-analysis and trial sequential analysis. Rev Bras Ter Intensiva 2018;30(4):487-95.
  • 30. Winck JC, Ambrosino N. COVID-19 pandemic and non invasive respiratory management: Every Goliath needs a David. An evidence based evaluation of problems. Pulmonology. 202010.1016/j.pulmoe.2020.04.013.
  • 31. Slessarev M, Cheng J, Ondrejicka M, Arntfield R, Critical Care Western Research G. Patient self-proning with highflow nasal cannula improves oxygenation in COVID-19 pneumonia. Can J Anaesth. 202010.1007/s12630-020- 01661-0.
  • 32. Lu X, Xu S. Therapeutic effect of high-flow nasal cannula on severe COVID-19 patients in a makeshift intensive-care unit: A case report. Medicine (Baltimore) 2020;99(21):e20393.
  • 33. Munshi L, Del Sorbo L, Adhikari NKJ, et al. Prone position for acute respiratory distress syndrome. a systematic review and meta-analysis. Ann Am Thorac Soc 2017;14(Supplement_4):S280-S8.
  • 34. Despres C, Brunin Y, Berthier F, Pili-Floury S, Besch G. Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients. Crit Care 2020;24(1):256.
  • 35. Xu Q, Wang T, Qin X, et al. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series. Crit Care 2020;24(1):250.
  • 36. Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med 2019;199(11):1368-76.
  • 37. Jeschke K, Bonnesen B, Hansen E, et al. Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. Eur Clin Respir J 2020;7(1).
  • 38. Lyons C, Callaghan M. Uses and mechanisms of apnoeic oxygenation: a narrative review. Anaesthesia 2019;74(4):497-507.
  • 39. Wu CN, Xia LZ, Li KH, et al. High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial. Br J Anaesth 2020;125(1):e166-e8.
  • 40. Brewster DJ, Chrimes N, Do TB, et al. Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group. Med J Aust 2020;212(10):472-81.
  • 41. Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID-19. J Am Coll Emerg Physicians Open 202010.1002/ emp2.12071.
  • 42. Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019;53(4).
  • 43. Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak. Can J Anaesth 2020;67(7):893-4.
  • 44. Clinical management of severe acute respiratory infection when Novel coronavirus (2019‐nCoV) infection is suspected: Interim Guidance. WHO/nCoV/Clinical/2020. [
  • 45. Harari SA, Vitacca M, Blasi F, et al. Managingthe Respiratory care of patients with COVID-19. [Available from: http:// www.aiponet.it :Italian Thoracic Society - Associazione ItalianaPneumologi Ospedalieri Societa Italiana Di Pneumologia;2020.
  • 46. Society AaNZI-sC. ANZICS COVID-19 Guidelines 2020 [Available from: http://cec.health.nsw.gov.au/__data/ assets/pdf_file/0004/572512/ANZICS-COVID-19- Guidelines-Version-1.pdf.
  • 47. Kluge S, Janssens U, Welte T, et al. German recommendations for critically ill patients with COVID-19. Medizinische Klinik-Intensivmedizin Und Notfallmedizin. 202010.1007/ s00063-020-00689-w.
  • 48. Kluge S, Janssens U, Welte T, et al. Recommendations for critically ill patients with COVID-19. Medizinische KlinikIntensivmedizin Und Notfallmedizin 2020;115(3):175-7.
  • 49. Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46(5):854-87.
APA Gürün Kaya A, Öz M, Erol S, Arslan F, CILEDAG A, KAYA A (2020). High flow nasal cannula in COVID-19: a literature review. , 168 - 174. 10.5578/tt.69807
Chicago Gürün Kaya Aslıhan,Öz Miraç,Erol Serhat,Arslan Fatma,CILEDAG AYDIN,KAYA AKIN High flow nasal cannula in COVID-19: a literature review. (2020): 168 - 174. 10.5578/tt.69807
MLA Gürün Kaya Aslıhan,Öz Miraç,Erol Serhat,Arslan Fatma,CILEDAG AYDIN,KAYA AKIN High flow nasal cannula in COVID-19: a literature review. , 2020, ss.168 - 174. 10.5578/tt.69807
AMA Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A High flow nasal cannula in COVID-19: a literature review. . 2020; 168 - 174. 10.5578/tt.69807
Vancouver Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A High flow nasal cannula in COVID-19: a literature review. . 2020; 168 - 174. 10.5578/tt.69807
IEEE Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A "High flow nasal cannula in COVID-19: a literature review." , ss.168 - 174, 2020. 10.5578/tt.69807
ISNAD Gürün Kaya, Aslıhan vd. "High flow nasal cannula in COVID-19: a literature review". (2020), 168-174. https://doi.org/10.5578/tt.69807
APA Gürün Kaya A, Öz M, Erol S, Arslan F, CILEDAG A, KAYA A (2020). High flow nasal cannula in COVID-19: a literature review. Tüberküloz ve Toraks, 68(2), 168 - 174. 10.5578/tt.69807
Chicago Gürün Kaya Aslıhan,Öz Miraç,Erol Serhat,Arslan Fatma,CILEDAG AYDIN,KAYA AKIN High flow nasal cannula in COVID-19: a literature review. Tüberküloz ve Toraks 68, no.2 (2020): 168 - 174. 10.5578/tt.69807
MLA Gürün Kaya Aslıhan,Öz Miraç,Erol Serhat,Arslan Fatma,CILEDAG AYDIN,KAYA AKIN High flow nasal cannula in COVID-19: a literature review. Tüberküloz ve Toraks, vol.68, no.2, 2020, ss.168 - 174. 10.5578/tt.69807
AMA Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A High flow nasal cannula in COVID-19: a literature review. Tüberküloz ve Toraks. 2020; 68(2): 168 - 174. 10.5578/tt.69807
Vancouver Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A High flow nasal cannula in COVID-19: a literature review. Tüberküloz ve Toraks. 2020; 68(2): 168 - 174. 10.5578/tt.69807
IEEE Gürün Kaya A,Öz M,Erol S,Arslan F,CILEDAG A,KAYA A "High flow nasal cannula in COVID-19: a literature review." Tüberküloz ve Toraks, 68, ss.168 - 174, 2020. 10.5578/tt.69807
ISNAD Gürün Kaya, Aslıhan vd. "High flow nasal cannula in COVID-19: a literature review". Tüberküloz ve Toraks 68/2 (2020), 168-174. https://doi.org/10.5578/tt.69807
Sayfa Oluşturulma Tarihi
17-04-2024 17:16

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları